Equillium, Inc. (EQ) Discusses Mechanistic Insights Linking AhR Signaling and miR-124 in Inflammatory Illness Transcript

Operator

Good morning, and welcome to the Equillium Digital Investor Occasion. [Operator Instructions] As a reminder, this name is being recorded, and a replay can be made obtainable on the Equillium web site following the conclusion of the occasion.

I might now like to show the decision over to your host, Stephen Connelly, Chief Scientific Officer at Equillium. Please go forward.

Stephen Connelly
Chief Scientific Officer & President

Thanks, Tara, and good morning, everybody, and thanks for becoming a member of at the moment’s webinar titled Insights to the Aryl Hydrocarbon Receptor and miR-124 Axis.

Now earlier than we begin, it most likely is smart to offer you a bit of little bit of context on this work from the outset, each the Aryl Hydrocarbon Receptor and miR-124 are two distinct organic molecules. And certainly, therapeutic methods modulating each of them have been proven to be efficient in treating ulcerative colitis. Nevertheless, knowledge exists from cells, animals and people that time to a extra direct and useful relationship between these two molecules. And regardless of the organic and therapeutic relevance, the paradoxical relationship between these two has remained elusive and controversial. So understanding this relationship has critically necessary implications for each mechanistic interpretation and rational improvement of therapies concentrating on the AhR/miR-124 Axis in inflammatory illness.

So offered right here